Altered serotonergic neurotransmission may contribute to the non-motor features commonly associated with Parkinson's disease (PD) such as sleep disorders. The 5-hydroxytryptophan (5-HTP) is the intermediate metabolite of L-tryptophan in the production of serotonin and melatonin. The purpose of this study was to compare the effects of 5-HTP to placebo on REM sleep behavior disorder (RBD) status in patients with PD.
Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease
Meloni, Mario;Figorilli, Michela;Carta, Manolo;Tamburrino, Ludovica;Sanna, Fabrizio;Defazio, Giovanni;Puligheddu, Monica
2022-01-01
Abstract
Altered serotonergic neurotransmission may contribute to the non-motor features commonly associated with Parkinson's disease (PD) such as sleep disorders. The 5-hydroxytryptophan (5-HTP) is the intermediate metabolite of L-tryptophan in the production of serotonin and melatonin. The purpose of this study was to compare the effects of 5-HTP to placebo on REM sleep behavior disorder (RBD) status in patients with PD.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Meloni2021_Article_PreliminaryFindingOfARandomize.pdf
accesso aperto
Tipologia:
versione editoriale
Dimensione
818.04 kB
Formato
Adobe PDF
|
818.04 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
